Acute Lymphoblastic Leukemia
A rapid-onset blood cancer where immature white blood cells (lymphoblasts) multiply uncontrollably in the bone marrow, crowding out healthy cells.
Emergency Management: Tumor Lysis Syndrome prophylaxis and treatment: Aggressive IV hydration, Allopurinol 300 mg/m2/day PO or Rasburicase 0.2 mg/kg IV x1 for severe hyperuricemia.
Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic malignancy characterized by the rapid proliferation of immature lymphoid progenitor cells (lymphoblasts) in the bone marrow and peripheral blood. This uncontrolled clonal expansion suppresses normal hematopoiesis, leading to cytopenias. It is the most common childhood cancer.
Detailed Overview
ALL arises from genetic mutations in a single lymphoid progenitor cell (B-cell or T-cell lineage). These mutations block normal cellular differentiation and promote unchecked proliferation. As lymphoblasts accumulate in the bone marrow, they crowd out normal hematopoietic elements, resulting in anemia, thrombocytopenia, and neutropenia. Leukemic cells can also infiltrate extramedullary sites, particularly the central nervous system (CNS), testes, and visceral organs like the liver and spleen. Classification is broadly divided into B-cell ALL (approx. 80%) and T-cell ALL (approx. 20%), with further subtyping based on cytogenetic abnormalities, such as the Philadelphia chromosome t(9;22), which carries significant prognostic and therapeutic implications.
Epidemiology & Demographics
Peak incidence occurs in children aged 2-5 years (approx. 75% of cases), with a second, smaller peak in adults > 50 years. Incidence is higher in males than females (1.3:1) and slightly higher in Hispanic and white populations compared to black populations.
Etiological Mechanism
The exact etiology is largely unknown. It is believed to result from a "two-hit" hypothesis involving prenatal genetic susceptibility followed by postnatal environmental triggers (e.g., delayed exposure to common childhood infections). Specific translocations (e.g., t(12;21), t(9;22)) drive the disease.
Primary Causes
De novo genetic mutations in lymphoid progenitors
Prior exposure to ionizing radiation
Prior treatment with alkylating agents or topoisomerase II inhibitors
Genetic alterations (e.g., ETV6-RUNX1 fusion, BCR-ABL1 fusion) in a B-cell or T-cell precursor disrupt transcription factors required for differentiation and activate signaling pathways (e.g., PI3K/AKT/mTOR, JAK/STAT) driving proliferation and survival. These arrested blasts proliferate rapidly in the bone marrow. Normal hematopoiesis is physically displaced and chemically inhibited by the leukemic clone, resulting in profound pancytopenia. Lymphoblasts egress into the bloodstream and disseminate to the CNS (via arachnoid invasion), testes, lymph nodes, and hepatosplenic tissues.
Diagnostic Criteria & Guidelines
Diagnosis is definitively established by bone marrow aspiration and biopsy demonstrating ≥ 20% lymphoblasts. Flow cytometry immunophenotyping is required to confirm the lymphoid lineage (e.g., CD19+, CD10+ for B-ALL; CD3+, CD7+ for T-ALL).
1. Induction: Vincristine 1.5 mg/m2 IV weekly, Dexamethasone 6 mg/m2 PO daily, Pegaspargase 2500 units/m2 IM/IV x1, and an anthracycline (e.g., Daunorubicin) for 4 weeks. 2. CNS Prophylaxis: Intrathecal Methotrexate given repeatedly. 3. Philadelphia positive (Ph+) ALL: Addition of a Tyrosine Kinase Inhibitor like Imatinib 400 mg PO daily or Dasatinib 140 mg PO daily.
Second-Line & Adjunctive Therapy
For relapsed or refractory B-ALL: Blinatumomab (CD19/CD3 bispecific T-cell engager) 28 mcg/day continuous IV infusion. Alternatively, Inotuzumab ozogamicin or Chimeric Antigen Receptor (CAR) T-cell therapy (Tisagenlecleucel).
Surgical & Procedural Management
Central venous catheter (Port-a-Cath or Hickman line) placement for prolonged chemotherapy administration. Surgery has no direct role in treating the primary disease.
Patient Counseling & Advice
Discuss the intensive and lengthy nature of treatment (2.5-3 years total). Counsel regarding risks of infertility, secondary malignancies, and the critical importance of adherence to maintenance therapy.
Follow-Up & Monitoring Schedule
Weekly CBCs during intensive phases. Bone marrow biopsies at the end of induction to assess Minimal Residual Disease (MRD) via flow cytometry or PCR, which strongly guides further therapy.
Preventive Strategies
There are no established preventative measures for ALL. Avoidance of known teratogens and unnecessary radiation during pregnancy is generally advised.
Highly dependent on age and cytogenetics. In children (age 1-9), the 5-year survival rate exceeds 90%. In adults, the 5-year survival drops to 30-40%. Favorable cytogenetics: t(12;21). Poor risk: t(9;22) (although improved with TKIs), t(4;11).